Quantcast

Latest Novartis Stories

2014-08-30 12:20:58

-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment regimen for HF-REF1 -- Study showed significantly more HF-REF patients on LCZ696 regimen were alive and had fewer hospitalizations than those given enalapril regimen1 -- Heart failure affects more than 600,000 Canadians18 and is responsible for 9 per...

2014-08-29 12:25:03

SILVER SPRING, Md., Aug. 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. District Court for the District of New Jersey has ruled in its favor in the company's case against Sandoz, Inc. regarding United Therapeutics' Remodulin(®) product. In his opinion, Judge Peter Sheridan ruled that U.S. Patent No. 6,765,117 is both valid and enforceable against Sandoz, Inc., and enjoined Sandoz from marketing its generic product until the...

2014-08-29 08:24:31

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous...

2014-08-26 12:29:13

DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Intranasal Drug Delivery Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Intranasal drug delivery system is a medical device used for the administration of drugs for the treatment of local diseases in the nose and paranasal sinus such as allergic and non-allergic rhinitis and sinusitis. The nose is considered to be an ideal administrative route...

2014-08-19 04:22:39

JERUSALEM, August 19, 2014 /PRNewswire/ -- Gamida Cell [http://www.gamida-cell.com ], a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG [http://www.novartis.com ] ("Novartis"). According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable...

2014-08-18 23:00:25

Georgina Wood is recognized as an NAPW VIP Woman of the Year for her outstanding leadership and commitment within her profession Garden City, NY (PRWEB) August 19, 2014 NAPW honors Georgina Wood as a 2014 Professional Woman of the Year. Ms. Wood is recognized with this prestigious distinction for leadership in pharmaceuticals. As the largest, most-recognized networking organization of professional women in the country, spanning virtually every industry and profession, the National...

2014-08-14 12:28:24

DALLAS, August 14, 2014 /PRNewswire/ -- LifeScienceIndustryResearch.com offers Animal/Veterinary Vaccines Market [Products (Livestock - Bovine, Companion - Canine, Poultry, Equine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Avian Influenza, Strangles), Technology (Live attenuated, DNA, Recombinant)] - Global Forecast to 2018 research report in its store. It says global animal vaccines market is in its growth phase and is poised to cross the $8 billion mark by...

2014-08-12 16:27:31

DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders....

2014-08-12 08:29:26

Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ending June 30, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented MEK inhibitors, binimetinib and selumetinib, are currently enrolling six Phase 3 trials, and each of our partners has...

2014-08-11 12:28:18

Twenty-five pharmaceutical companies being asked to adopt common principles re biosimilars on patient safety, lobbying and business partnerships. DETROIT, Aug. 11, 2014 /PRNewswire/ -- A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related